$2 5 million gift to CWRU provides permanent home for nurse leadership academy crainscleveland.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from crainscleveland.com Daily Mail and Mail on Sunday newspapers.
Maria Petrishina/Getty Images
Ask a woman in her 50s what some of the most uncomfortable symptoms of menopause are, and she’ll likely say hot flashes or night sweats. While this may be true, there are other, less commonly discussed symptoms that tend to be even more bothersome, not to mention permanent.
Some of these potentially life-altering symptoms can include intense vaginal dryness and pain with penetration; urgency and pain with urination; and overall feelings of genitourinary burning and irritation.
Called genitourinary syndrome of menopause (GSM), this constellation of symptoms affects as many as 27 to 84 percent of post-menopausal women and can “significantly impair health, sexual function, and quality of life,” according to a study published in September 2020 in the journal
Harrington Discovery Institute Announces New Fund to Advance Breakthrough Discoveries into Novel Treatments
The Advent-Harrington Impact Fund contributes to $215 million close of Advent Life Sciences’ funds focused on areas of high unmet medical need
Newswise CLEVELAND The transatlantic, not-for-profit medical accelerator, Harrington Discovery Institute (HDI) at University Hospitals, has collaborated with leading venture investor, Advent Life Sciences (‘Advent’) in the launch of the Advent-Harrington Impact Fund.
Advent’s new impact fund, structured alongside Advent Life Sciences Fund III, brings a total of $215 million to advance breakthrough discoveries into novel treatments for the benefit of patients and society.
Advent-Harrington Impact Fund, a market rate investment fund, breaks new ground through a partnership with a novel philanthropic vehicle at Morgan Stanley Wealth Management (MS GIFT Cures powered by HDI). Profits from Advent-Harrington Impact Fund are sha
University Hospitals Is First in Cleveland To Offer GT Medical Technologies New Targeted Therapy for Brain Tumors
GammaTile® Therapy Is Shown To Slow Brain Tumor Progression, Designed To Improve Patient and Caregiver Quality of Life
News provided by
Share this article
Share this article
CLEVELAND, Feb. 17, 2021 /PRNewswire/ A University Hospitals Cleveland Medical Center neurosurgeon is among the first in the region to begin offering GammaTile
® Therapy, a new approach to treating brain tumors. GammaTile Therapy is an FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) that is designed to delay tumor regrowth for patients with brain tumors while protecting healthy brain tissue. University Hospitals Seidman Cancer Center is the first to offer this to patients with brain tumors in Cleveland.
By the time the two-dose Moderna and Pfizer vaccines were approved and available, the region's health care industry says it was prepared. In many cases, providers stand ready to deliver far more vaccines than they are receiving.